Sentinel lymph node navigation surgery for pancreatic head cancers

  • Authors:
    • Tetsuo Ohta
    • Hirohisa Kitagawa
    • Masato Kayahara
    • Shin-Ichi Kinami
    • Itasu Ninomiya
    • Sachio Fushida
    • Takashi Fujimura
    • Gen-Ichi Nishimura
    • Koichi Shimizu
    • Shuangqin Yi
    • Koichi Miwa
  • View Affiliations

  • Published online on: March 1, 2003     https://doi.org/10.3892/or.10.2.315
  • Pages: 315-319
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Recently, sentinel lymph node (SN) concept has been validated for gastrointestinal and breast cancers. Our previous study has shown that the No. 13 posterior pancreaticoduodenal lymph node group constitutes the major regional drainage site from primary tumors in the pancreatic head, and that the status of these nodes predicts that of the No. 16 abdominal paraaortic lymph node group. Based on these results, we have developed SN navigation surgery for pancreatic cancer, in the search for more curable and less invasive surgery. In brief, 2% patent blue dye is injected into the peritumoral area. Approximately 5 min later, one or more blue-stained nodes within the area of the No. 13 lymph node group are identified and excised for intraoperative frozen section examination. The subsequent surgical decision-tree is as follows: i) if No. 13 SNs are negative, an extended No. 16 lymph node dissection is not performed to reduce morbidity, and ii) when cancer is found, the No. 16 lymph nodes are dissected completely. Since July 1997, nine of 21 patients scheduled to undergo an extended curative surgery underwent SN biopsy. SNs within the area of the No. 13 lymph node group were identified in 8 (89%) patients. An extended No. 16 lymph node dissection was avoided in 4 SN-negative patients. The overall 3-year survival rate of the 21 patients was 36%, and 4 patients (three SN-negative and one SN-positive patients) with stage IVa disease were alive 3 years after surgery. Three SN-negative patients underwent an extended curative pylorus-preserving pancreaticoduodenectomy (PpPD) with combined portal vein resection, but without an extended No. 16 dissection. In conclusion, SN biopsy and curative PpPD can increase curability, reduce morbidity, and provide long-term survival in patients with locally advanced pancreatic head cancer as an alternative to routine extended No. 16 lymph node dissection.

Related Articles

Journal Cover

March-April 2003
Volume 10 Issue 2

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Ohta T, Kitagawa H, Kayahara M, Kinami S, Ninomiya I, Fushida S, Fujimura T, Nishimura G, Shimizu K, Yi S, Yi S, et al: Sentinel lymph node navigation surgery for pancreatic head cancers. Oncol Rep 10: 315-319, 2003
APA
Ohta, T., Kitagawa, H., Kayahara, M., Kinami, S., Ninomiya, I., Fushida, S. ... Miwa, K. (2003). Sentinel lymph node navigation surgery for pancreatic head cancers. Oncology Reports, 10, 315-319. https://doi.org/10.3892/or.10.2.315
MLA
Ohta, T., Kitagawa, H., Kayahara, M., Kinami, S., Ninomiya, I., Fushida, S., Fujimura, T., Nishimura, G., Shimizu, K., Yi, S., Miwa, K."Sentinel lymph node navigation surgery for pancreatic head cancers". Oncology Reports 10.2 (2003): 315-319.
Chicago
Ohta, T., Kitagawa, H., Kayahara, M., Kinami, S., Ninomiya, I., Fushida, S., Fujimura, T., Nishimura, G., Shimizu, K., Yi, S., Miwa, K."Sentinel lymph node navigation surgery for pancreatic head cancers". Oncology Reports 10, no. 2 (2003): 315-319. https://doi.org/10.3892/or.10.2.315